Significance of nodal metastatic tumor characteristics in nodal metastasis and prognosis of patients with invasive ductal carcinoma of the breast

Cancer Science

Volumn 94, Issue 2, 2003, Pages 181-187

  Hasebe, Takahiro ^a   Sasaki, Satoshi ^a   Imoto, Shigeru ^b   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR GROWTH;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIFE TABLES; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM CIRCULATING CELLS; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038662900     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01416.x     Document Type: Article

References (22)

1. Fisher ER, Palekar A, Rockette H, Redmond C, Fisher B. Pathologic findings from the national surgical adjuvant breast project. (Protocol No. 4) V. Significance of axillary nodular micro- and macrometastases. Cancer 1978; 42: 2032-8.
2. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia A, Kinne DW. Axillary micro- and macrometastases in breast cancer. Prognostic significance of tumor size. Ann Surg 1981; 194: 585-91.
3. Fisher ER, Gregorio RM, Redmond C, Kim WS, Fisher B. Pathologic findings from the national surgical adjuvant breast project. (Protocol No. 4) The significance of extranodal extension of axillary metastases. Am J Clin Pathol 1976; 65: 439-45.
4. Mignano JE, Zahurak ML, Chakaravarthy A, Piantadosi S, Dooley WC, Gage I. Significance of axillary lymph node extranodal soft tissue extension and indicators for postmastectomy irradiation. Cancer 1999; 86: 1258-62.
5. Donegan WL, Stine SB, Samter TG. Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer. Cancer 1993; 72: 778-82.
6. Mambo NC, Gallager HS. Carcinoma of the breast. The prognostic significance of extranodal extension of axillary disease. Cancer 1977; 39: 2280-5.
7. Smith JA, Gamez-Araujo J, Gallager HS, White EC, McBride CM. Carcinoma of the breast. Analysis of total lymph node involvement versus level of metastasis. Cancer 1977; 39: 527-32.
8. Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970; 131: 79-88.
9. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes. J Clin Oncol 1996; 14: 3105-11.
10. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999; 17: 2334-40.
11. Fisher B, Bauer M, Wickerham L, Redmond CK, Fisher ER. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP Update. Cancer 1983; 52: 1551-7.
12. Sobin LH, Witteklnd CH. TNM Classification of malignant tumors. 5th ed. New York: Wiley-Liss Inc; 1997. p. 123-30.
13. Fisher BJ, Perera FE, Cooke AL, Opeitum A, Dar, AR, Venkatesan VM, Stitt L, Radwan JS. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy? Int J Radiat Oncol Biol Phys 1997; 38: 551-9.
14. Hartveit F, Skjaerven R, Maehle BO. Prognosis in breast cancer patients with tumour cells in the efferent vessels of their axillary nodes. J Pathol 1983; 139: 379-82.
15. Hartveit F. Paranodal tumour in breast cancer: extranodal extension versus vascular spread. J Pathol 1984; 144: 253-6.
16. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
19. Cooper LS, Gillett CE, Smith P, Fentiman IS, Barnes DM. Cell proliferation measured by MIB1 and timing of surgery for breast cancer. Br J Cancer 1998; 77: 1502-7.
20. Rudolph P, Alm P, Heidebrecht HJ, Bolte H, Ratjen V, Bldetorp H, Fermo M, Olsson H, Parwaresch R. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 1999; 91: 271-8.
21. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T. Expression of cell cycle-regulatory proteins Rb, pl6/MTS1, p27/KIP1, p2l/WAF1, cyclin DI and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 2000; 97: 468-72.
22. Crowe DL, Brown TN, Kim R, Smith SM, Lee MK. A c-fos/estrogen receptor fusion protein promotes cell cycle progression and proliferation of human cancer cell lines. Mol Cell Biol Res Commun 2000; 3: 243-8.